Update on osteoporosis therapy

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 4, 2006, Pages 755-763

  Borges, João Lindolfo C ^a,c   Bilezikian, John P ^b  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b Columbia University ^*  (United States)

^c Centro Clínico do Lago   (Brazil)

Author keywords

Bisphosphonates; Bone loss; Calcitonin; Calcium and vitamin D supplementation; Hormonal replacement; Selective estrogen receptor modulators; Teriparatide

Indexed keywords

EID: 33751220796     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000400020     Document Type: Review

References (44)

1. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
2. North American Menopause Society. Management of postmenopausal osteoporosis position statement of the North American Menopause Society. Menopause 2002;9:84-101.
3. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Available at: 〈http://www.nof.org/_vti_bin/ shtml.dll/physguide/index.htm〉. Accessed in April 27, 2005.
4. US Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General Rockville, MD. US Dept of Health and Human Services, Public Health Service, Office of the Surgeon General, 2004.
5. Going S, Lohman T, Houtkooper L, Metcalfe L, Flint-Wagner H, Blew R, et al. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. Osteoporos Int 2003;14:637-43.
6. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians effects on skeletal muscle. JAMA 1990;263:3029-34.
7. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
8. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-83.
9. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women a randomized controlled trial. Am J Med 1995;98:331-5.
10. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet. Available at: 〈http://ods.od.nih.gov/factsheets/ calcium.asp〉. Accessed in March 1, 2006.
11. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin D. Available at: 〈http://ods.od.nih.gov/ factsheets/vitamind.asp〉. Accessed in March 1, 2006.
12. NIH Consensus Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
13. O'Loughlin JL, Robitaille Y, Boivin JF, Suissa S. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 1993; 137: 342-54.
14. National Osteoporosis Foundation. Patient Info: Fall Prevention. Available at: 〈http://www.nof.org/patientinfo/fall_prevention.htm〉. Accessed in April 27, 2005.
15. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev 2004;3:CD001255.
16. Adachi K, Chole RA. Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP). Ann Otol Rhinol Laryngol 1990;99:738-41.
17. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-61.
18. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
19. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of Risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
20. Fosamax (Alendronate sodium) tablet and oral solution [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2004.
21. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of Alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
22. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of Alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
23. Actonel (Risedronate sodium tablets) [prescribing information]. Kansas City, MO: Aventis Pharmaceuticals Inc., 2004.
24. Boniva (Ibandronate sodium) tablets [prescribing information]. Nutley, NJ: Roche Laboratories Inc., 2005.
25. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral Ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
26. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61.
27. Grass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: An overview. Am J Med 2006;119:S3-11.
28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
29. Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly Risedronate in postmenopausal women. J Clin Densitom 2003;6:45-50.
30. Emkey R. Alendronate and Risedronate for the treatment of postmenopausal osteoporosis clinical profiles of the once-weekly and once-daily dosing formulations. MedGenMed 2004;6:6. [serial online]
31. Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of Risedronate. Endocr Pract 2002;8:202-7.
32. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, et al. Two-year results of once-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96.
33. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? J Bone Miner Res 2004;19:S448. [abstract M434]
34. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
35. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
36. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE [Multiple Outcomes of Raloxifene Evaluation] randomized trial. JAMA 1999;281:2189-97.
37. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene 4-year results from the MORE [Multiple Outcomes of Raloxifene Evaluation] trial. Breast Cancer Res Treat 2001;65:125-34.
38. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
39. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38.
40. Forteo (teriparatide rDNA origin) injection 750 μg/3 mL [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2004.
41. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
42. Miacalcin (calcitonin-salmon) nasal spray [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2003.
43. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267-76.
44. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, et al. Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-51.